Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 399.00K | 640.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 399.00K | 640.00K | 0.00 |
| Cost of Revenue | 66.57M | 61.91M | 58.34M | 53.34M | 45.58M |
| Gross Profit | -66.57M | -61.91M | -57.95M | -52.70M | -45.58M |
| SG&A Expenses | 28.18M | 25.89M | 24.84M | 20.83M | 17.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.75M | 87.80M | 83.18M | 74.17M | 62.66M |
| Operating Income | -94.75M | -87.80M | -82.78M | -73.53M | -62.66M |
| Income Before Tax | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
| EBIT | -94.75M | -87.80M | -82.78M | -73.53M | -62.66M |
| EBITDA | -93.96M | -87.03M | -82.03M | -73.06M | -62.40M |
| EPS Basic | -0.88 | -0.96 | -0.94 | -0.93 | -0.90 |
| Normalized Basic EPS | -0.55 | -0.60 | -0.59 | -0.58 | -0.56 |
| EPS Diluted | -0.88 | -0.96 | -0.94 | -0.93 | -0.90 |
| Normalized Diluted EPS | -0.55 | -0.60 | -0.59 | -0.58 | -0.56 |
| Average Basic Shares Outstanding | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M |
| Average Diluted Shares Outstanding | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
